Saturday, July 11, 2026

pharma · Retinitis Pigmentosa

GenSight Biologics

GenSight Biologics clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

paris, FR HQ
2013 Founded
34 Employees
EMA registrant Type
Company details
Status
Public
HQ
paris, FR
Founded
2013
Employees
34
Programs
2
Drugs
2
Patents
0
Intelligence · Clinical Programs

GenSight Biologics projects

2 ClinicalTrials.gov programs sponsored by GenSight Biologics.

GenSight Biologics has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. GS030_CLIN_001

    GenSight Biologics S.A.

    Retinitis Pigmentosa

    phase 2 small molecule active

    1 trial
  2. Lumevoq

    GenSight Biologics S.A.

    Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does GenSight Biologics have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.